JP2004508805A - 分泌及び膜貫通ポリペプチドとそれをコードする核酸 - Google Patents

分泌及び膜貫通ポリペプチドとそれをコードする核酸 Download PDF

Info

Publication number
JP2004508805A
JP2004508805A JP2001567332A JP2001567332A JP2004508805A JP 2004508805 A JP2004508805 A JP 2004508805A JP 2001567332 A JP2001567332 A JP 2001567332A JP 2001567332 A JP2001567332 A JP 2001567332A JP 2004508805 A JP2004508805 A JP 2004508805A
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
sequence
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001567332A
Other languages
English (en)
Japanese (ja)
Inventor
ベーカー，ケヴィン，ピー．
チェン，ジアン
デスノイヤース，ルーク
ゴッダード，オードリー
ゴドフスキー，ポール，ジェー．
ガーニー，オースティン，エル．
パン，ジェームス
スミス，ヴィクトリア
ワタナベ，コリン，ケー．
ウッド，ウィリアム，アイ．
ジャン，ゼミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/005601 external-priority patent/WO2000056889A2/fr
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/fr
Priority claimed from PCT/US2000/006884 external-priority patent/WO2001005972A1/fr
Priority claimed from PCT/US2000/008439 external-priority patent/WO2000073454A1/fr
Priority claimed from PCT/US2000/013705 external-priority patent/WO2000073445A2/fr
Priority claimed from PCT/US2000/014042 external-priority patent/WO2000077037A2/fr
Priority claimed from PCT/US2000/014941 external-priority patent/WO2000073348A2/fr
Priority claimed from PCT/US2000/015264 external-priority patent/WO2000073452A2/fr
Priority claimed from PCT/US2000/020710 external-priority patent/WO2001009327A2/fr
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/fr
Priority claimed from PCT/US2000/030952 external-priority patent/WO2001049715A2/fr
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/fr
Priority claimed from PCT/US2000/034956 external-priority patent/WO2001046420A2/fr
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2004508805A publication Critical patent/JP2004508805A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2001567332A 2000-03-01 2001-02-28 分泌及び膜貫通ポリペプチドとそれをコードする核酸 Withdrawn JP2004508805A (ja)

Applications Claiming Priority (40)

Application Number Priority Date Filing Date Title
PCT/US2000/005601 WO2000056889A2 (fr) 1999-03-23 2000-03-01 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
PCT/US2000/005841 WO2000053758A2 (fr) 1999-03-08 2000-03-02 Compositions et methodes de traitement des maladies immunitaires
US18720200P 2000-03-03 2000-03-03
US18696800P 2000-03-06 2000-03-06
US18932000P 2000-03-14 2000-03-14
US18932800P 2000-03-14 2000-03-14
PCT/US2000/006884 WO2001005972A1 (fr) 1999-07-20 2000-03-15 Compositions et methodes pour traiter des maladies d'ordre immunologique
US19082800P 2000-03-21 2000-03-21
US19131400P 2000-03-21 2000-03-21
US19100700P 2000-03-21 2000-03-21
US19104800P 2000-03-21 2000-03-21
US19265500P 2000-03-28 2000-03-28
US19305300P 2000-03-29 2000-03-29
US19303200P 2000-03-29 2000-03-29
PCT/US2000/008439 WO2000073454A1 (fr) 1999-06-02 2000-03-30 Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
US19444900P 2000-04-04 2000-04-04
US19464700P 2000-04-04 2000-04-04
US19600000P 2000-04-11 2000-04-11
US19618700P 2000-04-11 2000-04-11
US19597500P 2000-04-11 2000-04-11
US19682000P 2000-04-11 2000-04-11
US19669000P 2000-04-11 2000-04-11
US19858500P 2000-04-18 2000-04-18
US19812100P 2000-04-18 2000-04-18
US19939700P 2000-04-25 2000-04-25
US19965400P 2000-04-25 2000-04-25
US19955000P 2000-04-25 2000-04-25
US20151600P 2000-05-03 2000-05-03
PCT/US2000/013705 WO2000073445A2 (fr) 1999-06-02 2000-05-17 Promotion ou inhibition de l'angiogenese et de la cardiovascularisation
PCT/US2000/014042 WO2000077037A2 (fr) 1999-06-15 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant
PCT/US2000/014941 WO2000073348A2 (fr) 1999-06-02 2000-05-30 Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
PCT/US2000/015264 WO2000073452A2 (fr) 1999-06-02 2000-06-02 Compositions et methodes de traitement de maladies liees a l'immunite
US20983200P 2000-06-05 2000-06-05
PCT/US2000/020710 WO2001009327A2 (fr) 1999-07-28 2000-07-28 Procede de prevention de la deterioration ou de la mort des cellules de la retine et de traitement des troubles oculaires
US64484800A 2000-08-22 2000-08-22
PCT/US2000/023328 WO2001016318A2 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
PCT/US2000/030952 WO2001049715A2 (fr) 2000-01-06 2000-11-08 Methodes et compositions permettant d'inhiber la croissance cellulaire neoplasique
PCT/US2000/032678 WO2001040466A2 (fr) 1999-12-01 2000-12-01 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
PCT/US2000/034956 WO2001046420A2 (fr) 1999-12-23 2000-12-20 Polypeptides homologues de l'il-17 et leurs utilisations therapeutiques
PCT/US2001/006520 WO2001068848A2 (fr) 2000-03-01 2001-02-28 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2005264294A Division JP2006081548A (ja) 2000-03-01 2005-08-15 分泌及び膜貫通ポリペプチドとそれをコードする核酸
JP2008153789A Division JP2008301822A (ja) 2000-03-01 2008-06-12 分泌及び膜貫通ポリペプチドとそれをコードする核酸

Publications (1)

Publication Number Publication Date
JP2004508805A true JP2004508805A (ja) 2004-03-25

Family

ID=40231083

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2001567332A Withdrawn JP2004508805A (ja) 2000-03-01 2001-02-28 分泌及び膜貫通ポリペプチドとそれをコードする核酸
JP2005264294A Withdrawn JP2006081548A (ja) 2000-03-01 2005-08-15 分泌及び膜貫通ポリペプチドとそれをコードする核酸
JP2008153789A Withdrawn JP2008301822A (ja) 2000-03-01 2008-06-12 分泌及び膜貫通ポリペプチドとそれをコードする核酸

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2005264294A Withdrawn JP2006081548A (ja) 2000-03-01 2005-08-15 分泌及び膜貫通ポリペプチドとそれをコードする核酸
JP2008153789A Withdrawn JP2008301822A (ja) 2000-03-01 2008-06-12 分泌及び膜貫通ポリペプチドとそれをコードする核酸

Country Status (5)

Country Link
EP (1) EP1259614A2 (fr)
JP (3) JP2004508805A (fr)
AU (2) AU6802801A (fr)
CA (10) CA2534030A1 (fr)
WO (1) WO2001068848A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009168820A (ja) * 2005-03-11 2009-07-30 Genentech Inc 遺伝子破壊、組成物、およびそれに関連する方法

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009155A1 (fr) 1997-08-19 1999-02-25 Human Genome Sciences, Inc. 70 proteines secretees humaines
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
CA2301173C (fr) 1997-09-12 2015-04-14 Biogen, Inc. Recepteurs "train" riches en cysteine
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
ES2333385T3 (es) * 1997-09-17 2010-02-19 Human Genome Sciences, Inc. Proteina del tipo de interleuquina-17.
US20030039648A1 (en) 1998-09-16 2003-02-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030130182A1 (en) * 1997-11-05 2003-07-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
US20030009013A1 (en) 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US8133734B2 (en) 1999-03-16 2012-03-13 Human Genome Sciences, Inc. Kit comprising an antibody to interleukin 17 receptor-like protein
MXPA01011519A (es) * 1999-05-13 2003-08-20 Medical Res Council Homologos del receptor ox2.
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1623991A3 (fr) * 1999-09-01 2006-06-07 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
IL149340A0 (en) 1999-11-18 2002-11-10 Corvas Int Inc Nucleic acids encoding endotheliases, endotheliases and uses thereof
DK1897945T3 (da) * 1999-12-23 2012-05-07 Genentech Inc IL-17 homologe polypeptider og terapeutiske anvendelser deraf.
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20020155499A1 (en) * 2000-09-25 2002-10-24 Leiby Kevin R. 32624, a novel human UDP-glucuronosyl and glycosyl transferase family member and uses thereof
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
EP1280923A2 (fr) 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, un nouveau membre dans la famille de la trypsine humaine et son utilisation
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
AU2001268440A1 (en) * 2000-06-15 2002-01-08 Millennium Pharmaceuticals, Inc. 53320, a human acyltransferase and uses therefor
CA2413986A1 (fr) * 2000-06-22 2001-12-27 Biogen, Inc. Acides nucleiques et polypeptides de gp354
WO2002002624A2 (fr) * 2000-06-30 2002-01-10 Amgen, Inc. Molecules de type b7 et utilisation de ces molecules
JP2004527210A (ja) 2000-08-02 2004-09-09 ザ ジョンズ ホプキンス ユニバーシティー 内皮細胞発現パターンの評価法
EP1317472A4 (fr) * 2000-08-28 2005-04-27 Human Genome Sciences Inc 17 proteines humaines secretees
EP1313858A2 (fr) * 2000-09-01 2003-05-28 Millennium Pharmaceuticals, Inc. Kinases humaines 16658, 14223, et 16002, et utilisations
JP2004535758A (ja) 2000-11-14 2004-12-02 ブリストル−マイヤーズ　スクイブ　カンパニー リンパ様細胞ｌｓｉ−０１から分泌される新規なヒトセルピンをコードするポリヌクレオチド
DE10106835A1 (de) * 2001-02-14 2002-09-05 Basf Lynx Bioscience Ag Signaltransduktionsproteine 15B3, 15B3-1 und 15B3-2 und zugrundeliegende DNA-Sequenzen
WO2002064769A1 (fr) * 2001-02-15 2002-08-22 Shionogi & Co., Ltd. Nouveau marqueur de maladies
EP1873245A1 (fr) * 2001-02-28 2008-01-02 Genentech, Inc. Polypeptides homologue à l'interleukine-8 et utilisations thérapeutiques correspondantes
JP2004533222A (ja) * 2001-03-12 2004-11-04 インサイト・ゲノミックス・インコーポレイテッド 免疫グロブリンスーパーファミリータンパク質
WO2002072786A2 (fr) 2001-03-13 2002-09-19 Corvas International, Inc. Molecules d'acides nucleiques codant pour une serine protease transmembranaire 7, polypeptides codes et procedes associes
AU2002254357A1 (en) 2001-03-22 2002-10-08 Dendreon Corporation Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
CA2442089A1 (fr) 2001-03-27 2002-10-03 Dendreon San Diego Llc Molecules d'acide nucleique codant une serine protease transmembranaire 9, polypeptides codes et procedes fondes sur ces derniers
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
WO2002083921A2 (fr) 2001-04-10 2002-10-24 Agensys, Inc. Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
WO2002083856A2 (fr) 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Polynucleotides codant deux nouveaux recepteurs couples aux proteines g, hgprbmy28 et hgprbmy29, et leurs variants d'epissage
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
WO2002101075A2 (fr) 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Identification, evaluation, prevention et traitement du cancer du col de l'uterus : nouveaux genes, nouvelles compositions, nouvelles trousses et nouvelles methodes
AU2002322331B2 (en) * 2001-06-22 2008-01-03 Biogen Idec Ma Inc. Pancam nucleic acids and polypeptides
WO2003004530A1 (fr) * 2001-07-06 2003-01-16 Bayer Aktiengesellschaft Régulation de la protéine semblable à un récepteur de la somatostatine humaine
EP1436392A2 (fr) * 2001-07-26 2004-07-14 Genset S.A. Polynucleotides et polypeptides gmg-2 et leurs utilisations
JP4702819B2 (ja) 2001-08-01 2011-06-15 生化学工業株式会社 コンドロイチン合成酵素
EP1428881A4 (fr) 2001-08-23 2006-05-17 Japan Science & Tech Agency Regulateurs de la proliferation de cellules souches hematopoietiques et polynucleotides codant ces regulateurs
DE60238143D1 (de) 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
WO2003025162A2 (fr) * 2001-09-20 2003-03-27 Bayer Healthcare Ag Regulation du precurseur de la sous-unite alpha de prolyl 4-hydroxylase humaine
WO2003088898A2 (fr) * 2002-04-17 2003-10-30 Genentech, Inc. Compositions et procedes pour le diagnostic et le traitement de tumeurs
US20030147887A1 (en) * 2001-11-02 2003-08-07 Shen-Wu Wang B-cell lymphoma specific antigen for use in diagnosis and treatment of B-cell malignancies
AU2002359815A1 (en) 2001-12-19 2003-07-09 Immunex Corporation C-type lectin polypeptide, polynucleotide and methods of making and use thereof
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP2275118A3 (fr) 2002-05-29 2011-10-19 DeveloGen Aktiengesellschaft Proteines specifiques du pancreas
AU2003241979A1 (en) * 2002-05-31 2003-12-19 Hidetoshi Inoko Inflammatory skin disease-related slurp-2 gene and utilization thereof
US7232676B2 (en) * 2002-05-31 2007-06-19 Seikagaku Kogyo Kabushiki Kaisha Chondroitin synthase and nucleic acid encoding the enzyme
EP2305710A3 (fr) 2002-06-03 2013-05-29 Genentech, Inc. Bibliothèques de phages et anticorps synthétiques
US20060182755A1 (en) * 2002-09-11 2006-08-17 Genentech, Inc. Novel composition and methods for the treatment of psoriasis
DE10242016A1 (de) * 2002-09-11 2004-03-25 Esplora GmbH c/o TU Darmstadt Institut für Biochemie Verfahren zur Identifizierung BHS-spezifischer Proteine und Fragmente davon
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1577322A4 (fr) * 2002-12-26 2006-01-25 Takeda Pharmaceutical Nouvelles proteines et leur utilisation
CA2511556A1 (fr) * 2002-12-27 2004-07-29 Applied Research Systems Ars Holding N.V. Nouveaux polypeptides de type fibrilline
JP2006518193A (ja) * 2003-01-16 2006-08-10 ユニバーシティ オブ バージニア パテント ファウンデーション 精子特異的リゾチーム様タンパク質
US7312197B2 (en) 2003-02-24 2007-12-25 University Of Maryland, Baltimore Method of modifying glucose activity using polypeptides selectively expressed in fat tissue
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
EP2784084B2 (fr) 2003-07-08 2023-10-04 Novartis Pharma AG Polypeptides hétérologues IL-17 A/F et utilisations thérapeutiques associées
JP2007528721A (ja) 2003-08-14 2007-10-18 ダイアックス コーポレイション エンドセリアーゼ−２リガンド
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
EP1712619A4 (fr) * 2003-12-24 2008-01-02 Takeda Pharmaceutical Substance destinee a la prevention et au traitement du cancer
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
KR20070036089A (ko) 2004-07-02 2007-04-02 제넨테크, 인크. 비호지킨 림프종의 치료 방법 및 치료 조성물
EP1789070B1 (fr) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Influence du taj sur les fonctions neuronales
WO2006015373A2 (fr) 2004-08-04 2006-02-09 Amgen Inc Anticorps contre dkk-1
US7544659B2 (en) 2004-08-13 2009-06-09 Genentech, Inc. Promotion of axonal regeneration
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
WO2007067991A2 (fr) 2005-12-08 2007-06-14 Medarex, Inc. Anticorps monoclonaux humains se fixant a l'o8e
WO2007107774A2 (fr) * 2006-03-22 2007-09-27 Cartela R & D Ab Nouvelles méthodes de diagnostic et de traitement
CA2649387A1 (fr) * 2006-04-19 2008-03-27 Genentech, Inc. Nouvelles disruptions genetiques, compositions et procedes les concernant
ES2397661T3 (es) 2006-08-04 2013-03-08 Isis Pharmaceuticals, Inc. Composiciones y sus usos dirigidos a la diacilglicerol aciltransferasa 1
EP2069793B9 (fr) 2006-08-29 2017-08-16 Oxford BioTherapeutics Ltd Identification d'une protéine associée à un carcinome hépatocellulaire, à un glioblastome et à un cancer du poumon
US8058014B2 (en) 2006-09-29 2011-11-15 University Of Maryland, Baltimore Method of diagnosing or predicting disease states in a subject using omentin 1 and omentin 2
RU2474588C2 (ru) 2008-05-05 2013-02-10 Новиммун Са Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
WO2009149021A2 (fr) 2008-06-02 2009-12-10 Dana-Farber Cancer Institute, Inc. Peptides dérivés de xbp1, cd138 et cs1
CN102341412B (zh) 2009-03-05 2018-01-05 梅达雷克斯有限责任公司 特异于cadm1 的全人抗体
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
WO2013174404A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
JP6499079B2 (ja) 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
WO2014127785A1 (fr) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
WO2014146672A1 (fr) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
MX2018000412A (es) 2015-07-10 2018-03-14 Ionis Pharmaceuticals Inc Moduladores de diaciglicerol aciltransferasa 2 (dgat2).

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19817948A1 (de) * 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Endometrium-Tumor
CA2328895A1 (fr) * 1998-06-02 1999-12-09 Genentech, Inc. Proteines membranaires et acides nucleiques codant ces proteines
WO2000058473A2 (fr) * 1999-03-31 2000-10-05 Curagen Corporation Acides nucleiques comprenant des phases de lecture ouverte codant des polypeptides; «orfx»
JP2004522402A (ja) * 1999-06-02 2004-07-29 ジェネンテック・インコーポレーテッド 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸
EP1248800A2 (fr) * 1999-11-30 2002-10-16 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
CA2399776A1 (fr) * 2000-02-03 2001-08-09 Hyseq, Inc. Acides nucleiques et polypeptides
CA2420140A1 (fr) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions et procedes de diagnostic et traitement de tumeurs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009168820A (ja) * 2005-03-11 2009-07-30 Genentech Inc 遺伝子破壊、組成物、およびそれに関連する方法

Also Published As

Publication number Publication date
JP2008301822A (ja) 2008-12-18
CA2533991A1 (fr) 2001-09-20
JP2006081548A (ja) 2006-03-30
CA2534186A1 (fr) 2001-09-20
CA2401448A1 (fr) 2001-09-20
AU2001268028A1 (en) 2001-09-24
WO2001068848A3 (fr) 2002-08-29
CA2533903A1 (fr) 2001-09-20
CA2534030A1 (fr) 2001-09-20
CA2539214A1 (fr) 2001-09-20
CA2534018A1 (fr) 2001-09-20
CA2534391A1 (fr) 2001-09-20
AU6802801A (en) 2001-09-24
CA2531917A1 (fr) 2001-09-20
WO2001068848A2 (fr) 2001-09-20
EP1259614A2 (fr) 2002-11-27
CA2533831A1 (fr) 2001-09-20

Similar Documents

Publication Publication Date Title
US7211645B2 (en) PRO268 polypeptides
US7307144B2 (en) PRO 6493 polypeptides
JP2004508805A (ja) 分泌及び膜貫通ポリペプチドとそれをコードする核酸
US20030017541A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050202526A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7388073B2 (en) PRO9835 polypeptides
US7291703B2 (en) PRO1508 polypeptides

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20050513

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20050525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070409

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080625

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20080731

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20080919

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100310